|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Greten TF, Wang XW and Korangy F: Current
concepts of immune based treatments for patients with HCC: From
basic science to novel treatment approaches. Gut. 64:842–848. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Z and Rana TM: Therapeutic targeting of
microRNAs: Current status and future challenges. Nat Rev Drug
Discov. 13:622–638. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dragomir MP, Knutsen E and Calin GA:
SnapShot: Unconventional miRNA functions. Cell. 174:1038–1038.e1.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hayes CN and Chayama K: MicroRNAs as
biomarkers for liver disease and hepatocellular carcinoma. Int J
Mol Sci. 17:2802016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Du H, Xu Q, Xiao S, Wu Z, Gong J, Liu C,
Ren G and Wu H: MicroRNA-424-5p acts as a potential biomarker and
inhibits proliferation and invasion in hepatocellular carcinoma by
targeting TRIM29. Life Sci. 224:1–11. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang H, Lv W, Sun W, Bi Q and Hao Y:
miR-505 inhibits cell growth and EMT by targeting MAP3K3 through
the AKT-NFκB pathway in NSCLC cells. Int J Mol Med. 43:1203–1216.
2019.PubMed/NCBI
|
|
10
|
Yang L, Zhang S, Guo K, Huang H, Qi S, Yao
J and Zhang Z: miR-125a restrains cell migration and invasion by
targeting STAT3 in gastric cancer cells. Onco Targets Ther.
12:205–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong XZ, Song Y, Lu YP, Hu Y, Liu P and
Zhang L: Sanguinarine inhibits the proliferation of BGC-823 gastric
cancer cells via regulating miR-96-5p/miR-29c-3p and the MAPK/JNK
signaling pathway. J Nat Med. 73:777–788. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen G, Zhou T, Li Y, Yu Z and Sun L: p53
target miR-29c-3p suppresses colon cancer cell invasion and
migration through inhibition of PHLDB2. Biochem Biophys Res Commun.
487:90–95. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu Y, Tang L, Zhang Z, Li S, Liang S, Ji
L, Yang B, Liu Y and Wei W: Long noncoding RNA TUG1/miR-29c axis
affects cell proliferation, invasion, and migration in human
pancreatic cancer. Dis Markers. 22:68570422018.
|
|
14
|
Fang R, Huang Y, Xie J, Zhang J and Ji X:
Downregulation of miR-29c-3p is associated with a poor prognosis in
patients with laryngeal squamous cell carcinoma. Diagn Pathol.
14:1092019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Yu T, Li W, Li M, Zuo Q, Zou Q and
Xiao B: The miR-29c-KIAA1199 axis regulates gastric cancer
migration by binding with WBP11 and PTP4A3. Oncogene. 38:3134–3150.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang S, Jin J, Tian X and Wu L:
sa-miR-29c-3p regulates biological function of colorectal cancer by
targeting SPARC. Oncotarget. 8:104508–104524. 2017.PubMed/NCBI
|
|
17
|
Wu H, Zhang W, Wu Z, Liu Y, Shi Y, Gong J,
Shen W and Liu C: miR-29c-3p regulates DNMT3B and LATS1 methylation
to inhibit tumor progression in hepatocellular carcinoma. Cell
Death Dis. 18:482019. View Article : Google Scholar
|
|
18
|
Lopes CB, Magalhães LL, Teófilo CR, Alves
APNN, Montenegro RC, Negrini M and Ribeiro-Dos-Santos Â:
Differential expression of hsa-miR-221, hsa-miR-21, hsa-miR-135b,
and hsa-miR-29c suggests a field effect in oral cancer. BMC Cancer.
18:7212018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li W, Yi J, Zheng X, Liu S, Fu W, Ren L,
Li L, Hoon DSB, Wang J and Du G: miR-29c plays a suppressive role
in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway. Clin
Epigenetics. 10:642018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chhabra R: miRNA and methylation: A
multifaceted liaison. Chembiochem. 16:195–203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang
L, Zhang H, Chen X, Yang Y and Liu G: miRNA-29c suppresses lung
cancer cell adhesion to extracellular matrix and metastasis by
targeting integrin beta1 and matrix metalloproteinase2 (MMP2). PLoS
One. 8:e701922013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li L, Shou H, Wang Q and Liu S:
Investigation of the potential theranostic role of KDM5B/miR-29c
signaling axis in paclitaxel resistant endometrial carcinoma. Gene.
694:76–82. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morita S, Horii T, Kimura M, Ochiya T,
Tajima S and Hatada I: miR-29 represses the activities of DNA
methyltransferases and DNA demethylases. Int J Mol Sci.
14:14647–14658. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Bi N, Wu L, Ding X, Men Y, Zhou W,
Li L, Zhang W, Shi S, Song Y and Wang L: MicroRNA-29c functions as
a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol
Cancer. 16:502017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reymond A, Meroni G, Fantozzi A, Merla G,
Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et
al: The tripartite motif family identifies cell compartments. EMBO
J. 20:2140–2151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song H, Liu B, Huai W, Yu Z, Wang W, Zhao
J, Han L, Jiang G, Zhang L, Gao C and Zhao W: The E3 ubiquitin
ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting
proteasomal degradation of NLRP3. Nat Commun. 7:137272016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu C, Chen S, Guo Y and Sun C: Oncogenic
TRIM31 confers gemcitabine resistance in pancreatic cancer via
activating the NF-κB signaling pathway. Theranostics. 8:3224–3236.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li H, Zhang Y, Hai J, Wang J, Zhao B, Du L
and Geng X: Knockdown of TRIM31 suppresses proliferation and
invasion of gallbladder cancer cells by down-regulating MMP2/9
through the PI3K/Akt signaling pathway. Biomed Pharmacother.
103:1272–1278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ra EA, Lee TA, Won Kim S, Park A, Choi HJ,
Jang I, Kang S, Hee Cheon J, Cho JW, Eun Lee J, et al: TRIM31
promotes Atg5/Atg7-independent autophagy in intestinal cells. Nat
Commun. 7:117262016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Scott DC, Sviderskiy VO, Monda JK, Lydeard
JR, Cho SE, Harper JW and Schulman BA: Structure of a RING E3
trapped in action reveals ligation mechanism for the ubiquitin-like
protein NEDD8. Cell. 157:1671–1684. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sato T, Takahashi H, Hatakeyama S, Iguchi
A and Ariga T: The TRIM-FLMN protein TRIM45 directly interacts with
RACK1 and negatively regulates PKC-mediated signaling pathway.
Oncogene. 34:1280–1291. 2015. View Article : Google Scholar : PubMed/NCBI
|
